Introduction {#Sec1}
============

*Rauvolfia* genus of the Apocynaceae family, comprising about 60 species, is mainly distributed in America, Africa, Asia, and Oceania \[[@CR1]\]. Plants of this genus are a rich source of monoterpenoid indole alkaloids, which have attracted great interests from biological and therapeutic aspects \[[@CR2]--[@CR5]\]. As part of a BioBioPha \[<http://www.chemlib.cn>\] objective to assemble a large-scale natural product library valuable in the discovery of new drug leads from nature, previous chemical study on the ethanolic extract of *Rauvolfia tetraphylla* had resulted in the isolation of five new indole alkaloids, rauvotetraphyllines A--E \[[@CR6]\]. Further investigation of the remaining components led to the isolation of another five new alkaloids bearing an unusual 2,2-dimethyl-4-oxopiperidin-6-yl moiety, rauvotetraphyllines F--H (**1**, **3**, **4**), 17-*epi*-rauvotetraphylline F (**2**) and 21-*epi*-rauvotetraphylline H (**5**). The present paper describes the isolation, structure elucidation, and cytotoxic evaluation of the new compounds.

Results and Discussion {#Sec2}
======================

Compound **1**, obtained as amorphous powder, possessed a molecular formula of C~31~H~41~N~3~O~7~, as evidenced by HR-ESI-MS (pos.) at *m*/*z* 568.3025 (calcd for C~31~H~42~N~3~O~7~, 568.3022), in combination with NMR spectra (Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}), requiring 13 degrees of unsaturation. In the UV spectrum, two characteristic maxima at 225 and 281 were detected, suggesting the existence of an unsubstituted indole chromophore \[[@CR7]\]. The IR spectrum showed the presence of OH/NH (3404 cm^−1^) functionalities. The 1D-NMR spectra (Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}) revealed the presence of an unsubstituted indole moiety \[*δ*~H~ 7.38 (1H, d, *J* = 7.8 Hz), 7.26 (1H, d, *J* = 8.0 Hz), 7.02 (1H, dd, *J* = 8.0, 7.3 Hz), and 6.95 (1H, dd, *J* = 7.8, 7.3, Hz); *δ*~C~ 139.7 (s), 138.2 (s), 128.9 (s), 121.9 (d), 119.7 (d), 118.5 (d), 111.9 (d), and 104.0 (s)\], an ethylidene group \[*δ*~H~ 1.75 (3H, d, *J* = 6.9 Hz) and 5.93 (1H, q, *J* = 6.9 Hz); *δ*~C~ 14.3 (q) and 125.2 (d)\], and a glucose unit \[*δ*~H~ 4.64 (1H, d, *J* = 7.9 Hz), 3.29 (1H, m), 3.37 (1H, m), 3.28 (2H, m), 3.60 (1H, dd, *J* = 11.9, 4.9 Hz), and 3.74 (1H, dd, *J* = 11.9, 1.6 Hz); *δ*~C~ 103.2 (d), 78.0 (d), 77.9 (d), 75.4 (d), 71.4 (d), and 62.7 (t)\]. Comparison of its ^13^C NMR data with those of rauvotetraphylline B \[[@CR6]\] revealed a remarkable resemblance except for a prominent difference as follows: the carbon signals assigned to 4,6-dimethylpyrid-2-yl unit in rauvotetraphylline B were not present, and there was a set of newly arisen resonances \[*δ*~C~ 56.5 (d), 47.4 (t), 213.2 (s), 55.7 (t), 55.5 (s), 25.6 (q), and 31.9 (q)\] determined as a 2,2-dimethyl-4-oxopiperidin-6-yl moiety by HMBC correlations (Fig. [1](#Fig1){ref-type="fig"}) from H-17 to C-23, H-22 to C-23 and C-24, and H-24 to C-22, C-23, C-25, C-26, and C-27. The piperidinyl moiety was linked to C-16 through C-16--C-17 bond by HMBC correlations from H-16 to C-17 and C-22 and ^1^H-^1^H COSY correlation of H-16/H-17 (Fig. [1](#Fig1){ref-type="fig"}).Table 1^1^H NMR Data for Compounds **1**--**3** (*δ* in ppm, *J* in Hz)No.**1** ^a^**2** ^a^**3** ^b^34.67 (dd, 10.1, 2.1)4.70 (br d, 10.5)4.07 (br d, 10.4)52.88 (dd, 7.0, 5.3)3.20 (dd, 7.0, 5.5)2.92 (dd, 7.5, 5.3)6*α*3.10 (dd, 15.2, 5.3)3.16 (dd, 15.4, 5.5)3.08 (dd, 15.3, 5.3)6*β*2.64 (d, 15.2)2.91 (d, 15.4)2.53 (d, 15.3)97.38 (d, 7.8)7.43 (d, 7.7)7.44 (d, 7.6)106.95 (dd, 7.8, 7.3)6.97 (dd, 7.7, 7.2)7.09 (dd, 7.6, 7.3)117.02 (dd, 8.0, 7.3)7.04 (dd, 8.0, 7.2)7.13 (dd, 7.8, 7.3)127.26 (d, 8.0)7.27 (d, 8.0)7.26 (d, 7.8)14*α*\
14*β*2.10 (m)\
1.64 (m)2.14 (m)\
1.66 (m)2.01 (m)\
1.68 (m)153.26 (br s)2.79 (br s)3.12 (br s)161.62 (ddd, 9.0, 7.0, 0.9)1.65 (m)1.53 (ddd, 9.4, 7.3, 0.9)172.80 (ddd, 12.1, 9.0, 2.7)2.75 (ddd, 12.2, 9.2, 2.8)2.95 (ddd, 11.6, 9.4, 2.7)181.75 (d, 6.9)1.71 (d, 6.9)1.65 (d, 6.8)195.93 (q, 6.9)5.95 (q, 6.9)5.34 (q, 6.8)214.96 (s)5.03 (s)3.55 (2H, s)22*α*\
22*β*2.41 (br d, 12.3)\
2.12 (dd, 12.3, 12.1)2.43 (br d, 12.5)\
1.95 (dd, 12.5, 12.2)2.47 (br d, 12.7)\
1.92 (dd, 12.7, 11.6)24*α*2.15 (dd, 13.0, 1.3)2.16 (dd, 13.3, 0.8)2.25 (dd, 13.1, 1.3)24*β*2.26 (d, 13.0)2.29 (d, 13.3)2.12 (d, 13.1)260.95 (s)0.98 (s)0.99 (s)271.19 (s)1.29 (s)1.19 (s)1′4.64 (d, 7.9)4.65 (d, 7.8)2′3.29 (m)3.30 (m)3′3.37 (m)3.37 (m)4′3.28 (m, overlap)3.29 (m, overlap)5′3.28 (m, overlap)3.29 (m, overlap)6′a3.60 (dd, 11.9, 4.9)3.60 (dd, 11.9, 4.9)6′b3.74 (dd, 11.9, 1.6)3.76 (br d, 11.9)1-NH8.08 (s)^a^Measured in methanol-*d* ~4~ (3.30 ppm)^b^Measured in CDCl~3~ (7.26 ppm)Fig. 1Key HMBC and ^1^H--^1^H COSY correlations of **1**

The relative configuration of **1** was established by NMR analysis based on computer-generated 3D drawing with minimized energy by MM2 calculation (Fig. [2](#Fig2){ref-type="fig"}). ROESY correlations of H-16↔H-6*β*/H-14*β* and H-5↔H-21 suggested that **1** had the same stereochemistry as rauvotetraphylline B. The *E*-geometry of the ethylidene was indicated from ROESY correlations of H-15↔Me-18 and H-19↔H-21. The *anti* relationship of H-16 and H-17 was suggested by the large coupling constant (*J*~16,17~ = 9.0 Hz), which could also be explained by that the molecule favors the conformation in which larger substituents are in the *anti* position. This was further supported by ROESY correlations of H-17↔Me-18. The *R\** configuration of C-17 was implied by ROESY correlations of H-6*β*↔H-22*β* and Me-18↔Me-26 (Fig. [2](#Fig2){ref-type="fig"}). Another noteworthy observation is that the chemical shift of H-15 (*δ*~H~ 3.26) in **1** was relatively deshielded compared to that of H-15 (*δ*~H~ 2.79) in its 17-epimer **2** (vide infra). This is attributed to paramagnetic deshielding caused by the proximity of the NH nitrogen atom to H-15 (Fig. [2](#Fig2){ref-type="fig"}). Thus, the structure of **1** was established as shown and named rauvotetraphylline F.Fig. 2Key ROESY correlations of **1** and **2**

Compound **2**, isolated as amorphous powder, had the same molecular formula as **1** based on HR-ESI-MS (pos.), showing a quasi-molecular ion peak at *m*/*z* 568.3031 (calcd for C~31~H~42~N~3~O~7~, 568.3022). The ^1^H and ^13^C NMR spectra of **2** (Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}) were very similar in all respects to those of **2** except for the chemical shifts of H-5, H-6*β*, and H-15 in the ^1^H NMR spectrum. This discrepancy proved that compound **2** is a C-17 epimer of **1** while applying the same analysis carried out for **1**. The paramagnetic deshielding experienced by H-15 in **1** was now experienced by H-5 and H-6*β* instead in **2** (Fig. [2](#Fig2){ref-type="fig"}), implying the *S\** configuration of C-17. This was further verified by strong ROESY correlations between H-22*α* and H-15/Me-18 and no correlation between Me-26 and Me-18. Therefore, the structure of **1** was elucidated as shown and named 17-*epi*-rauvotetraphylline F.

Compound **3** was obtained as amorphous powder. Its HR-ESI-MS revealed an \[M + H\]^+^ peak at *m*/*z* 390.2538 (calcd for C~25~H~32~N~3~O, 390.2545), suggesting the molecular formula C~25~H~31~N~3~O. The NMR data (Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}) were closely related to those of **1** except for the signals of a methylene group in **3** instead of an oxygenated methine group in **1**, and the absence of a series of glucose resonances. The configuration of C-17 was designated as *R\** based on Me-18 showing ROESY correlation to Me-26, but no correlation to H-22. Consequently, the structure of **3** was determined and named rauvotetraphylline G.

Compound **4** was isolated as amorphous powder. Its molecular formula was determined as C~27~H~33~N~3~O~3~ by positive HR-ESI-MS at *m*/*z* 448.2613 (calcd for C~27~H~34~N~3~O~3~, 448.2600). The ^13^C NMR data (Table [3](#Tab3){ref-type="table"}) were very similar to those of perakine \[[@CR8]\]. The prominent difference between them was the aldehyde group in perakine changing into a 2,2-dimethyl-4-oxopiperidin-6-yl moiety \[*δ*~C~ 54.8 (d), 47.2 (t), 210.4 (s), 55.4 (t), 54.5 (s), 25.2 (q), 32.2 (q)\] on the basis of HMBC correlations (Fig. [3](#Fig3){ref-type="fig"}) from H-21 to C-15 and C-20, H-22 to C-20, C-21, C-23, and C-24, and Me-26 to C-24, C-25, and C-27. The ROESY correlations (Fig. [4](#Fig4){ref-type="fig"}) of H-19↔H-3/H-14*α*, H-14*β*↔H-17, Me-18↔H-20, and H-20↔H-5/H-16 indicated that **4** possessed the same stereochemical characteristics as perakine. The *R\** configuration of C-21 was indicated by ROESY correlations of H-21↔H-14*α*/H-19, H-22*α*↔H-19, and H-22*β*↔Me-18, which was further supported by comparison of the ^1^H NMR spectra of **4** and its C-21 epimer **5** (vide infra) (Table [2](#Tab2){ref-type="table"}). The proximity of the NH nitrogen atom to H-15 in **4** caused a marked downfield shift of H-15 (Δ = 0.30 ppm) (Fig. [4](#Fig4){ref-type="fig"}). Hence, the structure of **4** was assigned as shown and named rauvotetraphylline H.Fig. 3Key HMBC correlations of **4**Fig. 4Key ROESY correlations of **4** and **5**Table 2^1^H NMR Data for Compounds **4** and **5** (*δ* in ppm, *J* in Hz)No.**45**34.14 (d, 9.7)4.16 (d, 9.4)53.64 (dd, 6.6, 4.9)3.63 (dd, 6.1, 4.8)6*α*\
6*β*1.60 (d, 11.9)\
2.79 (dd, 11.9, 4.9)1.61 (d, 11.9)\
2.78 (dd, 11.9, 4.8)97.47 (d, 7.3)7.45 (d, 7.3)107.22 (dd, 7.6, 7.3)7.20 (dd, 7.6, 7.3)117.39 (dd, 7.7, 7.6)7.37 (dd, 7.7, 7.6)127.61 (d, 7.7)7.60 (d, 7.7)14*α*\
14*β*1.89 (dd, 14.7, 9.7)\
1.52 (dd, 14.7, 4.4)1.83 (dd, 14.9, 9.4)\
1.51 (dd, 14.9, 3.1)152.62 (m)2.32 (m, overlap)162.34 (dd, 6.6, 5.0)2.32 (m, overlap)174.99 (s)4.95 (s)181.29 (d, 6.5)1.44 (d, 6.4)192.65 (m)2.76 (m)201.25 (m)1.20 (m)213.16 (ddd, 11.8, 8.5, 2.7)3.16 (ddd, 11.2, 8.7, 2.5)22*α*2.43 (br. d, 12.9)2.52 (br. d, 13.4)22*β*2.12 (dd, 12.9, 11.8)1.92 (dd, 13.4, 11.2)24*α*2.28 (br. d, 14.4)2.31 (br. d, 13.5)24*β*2.25 (d, 14.4)2.19 (d, 13.5)261.06 (s)1.08 (s)271.27 (s)1.28 (s)OAc2.17 (s)2.16 (s)Measured in CDCl~3~ (7.26 ppm)

Compound **5**, obtained as amorphous powder, had the same molecular formula as **4**, possessing a quasi-molecular ion peak at *m*/*z* 448.2602 (calcd for C~27~H~34~N~3~O~3~, 448.2600). The ^1^H and ^13^C NMR spectra of **5** (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}) were almost identical to those of **4** except for the upfield shift of H-15 (Δ = −0.30 ppm) and downfield shifts of Me-18 (Δ = 0.15 ppm) and H-19 (Δ = 0.11 ppm) in the ^1^H NMR spectrum. This can be rationalized in terms of paramagnetic deshielding experienced by Me-18 and H-19 in **5** and H-15 in **4** (Fig. [4](#Fig4){ref-type="fig"}), revealing the *S\** configuration of C-21. This was further supported by significant ROESY correlation (Fig. [4](#Fig4){ref-type="fig"}) of H-22*α*↔H-15 and no correlation of H-22*α*↔H-19 or H-22*β*↔Me-18. Therefore, the structure of **5** was elucidated as shown and named 21-*epi*-rauvotetraphylline H.Table 3^13^C NMR Data for Compounds **1**--**5** (*δ* in ppm)No.**1** ^a^**2** ^a^**3** ^b^**4** ^b^**5** ^b^2139.7 (s)139.0 (s)138.3 (s)183.2 (s)183.2 (s)344.6 (d)44.8 (d)50.0 (d)56.8 (d)56.8 (d)553.4 (d)55.4 (d)54.8 (d)50.7 (d)50.8 (d)628.3 (t)28.9 (t)27.6 (t)37.6 (t)37.6 (t)7104.0 (s)104.5 (s)103.9 (s)64.8 (s)64.8 (s)8128.9 (s)128.9 (s)127.5 (s)136.3 (s)136.3 (s)9118.5 (d)118.7 (d)117.9 (d)123.8 (d)123.8 (d)10119.7 (d)119.7 (d)119.4 (d)125.4 (d)125.4 (d)11121.9 (d)122.0 (d)121.4 (d)128.6 (d)128.6 (d)12111.9 (d)112.0 (d)110.9 (d)120.9 (d)120.9 (d)13138.2 (s)138.3 (s)136.3 (s)156.5 (s)156.5 (s)1434.7 (t)34.8 (t)34.5 (t)22.0 (t)22.2 (t)1529.2 (d)29.3 (d)27.4 (d)27.2 (d)27.0 (d)1648.5 (d)48.2 (d)48.1 (d)49.2 (d)49.4 (d)1756.5 (d)57.6 (d)54.8 (d)78.3 (d)78.2 (d)1814.3 (q)13.8 (q)13.6 (q)20.4 (q)21.3 (q)19125.2 (d)124.9 (d)116.4 (d)53.1 (d)55.7 (d)20137.6 (s)137.4 (s)135.8 (s)49.4 (d)49.4 (d)2191.7 (d)91.7 (d)56.0 (t)51.8 (d)53.7 (d)2247.4 (t)48.2 (t)47.2 (t)47.8 (t)48.0 (t)23213.2 (s)212.9 (s)210.4 (s)209.6 (s)209.4 (s)2455.7 (t)55.6 (t)55.4 (t)54.6 (t)55.1 (t)2555.5 (s)55.6 (s)54.5 (s)54.0 (s)54.5 (s)2625.6 (q)25.4 (q)25.2 (q)25.4 (q)25.4 (q)2731.9 (q)31.8 (q)32.2 (q)32.1 (q)32.2 (q)1′103.2 (d)103.3 (d)2′75.4 (d)75.3 (d)3′78.0 (d)78.0 (d)4′71.4 (d)71.5 (d)5′77.9 (d)78.0 (d)6′62.7 (t)62.7 (t)CH~3~COO21.1 (q)21.1 (q)CH~3~COO170.1 (s)170.0 (s)^a^Measured in methanol-*d* ~4~ (49.0 ppm)^b^Measured in CDCl~3~ (77.0 ppm)

The contribution of artifacts on structural diversity of alkaloids from *Rauvolfia* species is not ignorable as acidic or basic conditions are often used during isolation process, in spite that many artifacts from this genus are generally presented in literatures as naturally occurring compounds \[[@CR9]\]. Considering that the presence of aldehyde group at C-16/C-20 is common for sarpagine/perakine type alkaloids \[[@CR8], [@CR10], [@CR11]\], it's plausible to deduce that, like triacetonamine \[[@CR12]\], a common artifact of plant extractions, the 2,2-dimethyl-4-oxopiperidine moiety might also be an artifact produced by reaction of aldehyde group with acetone/ammonia since the latter were used as eluents during the isolation procedures. These artifacts represent a unique type of sarpagine/perakine series bearing an unusual piperidine unit brought about by using common eluents.

All of the isolated compounds were evaluated for their in vitro growth inhibitory effects against five human tumor cell lines (HL-60, SMMC-7721, A-549, MCF-7 and SW-480) with cisplatin and taxol serving as positive controls by the MTT method \[[@CR13]\]. Regrettably, all tested compounds were inactive (IC~50~ values \> 40 μM).

Experimental Section {#Sec3}
====================

General Experimental Procedures {#Sec4}
-------------------------------

Optical rotations were measured on a Jasco P-1020 automatic digital polarimeter. UV data were obtained from online HPLC analysis. IR spectra (KBr) were obtained on a Bruker Tensor-27 infrared spectrophotometer. NMR spectra were acquired with a Bruker DRX-500 or Bruker Avance III 600 instrument (Bruker BioSpin GmbH, Rheinstetten, Germany) with deuterated solvent signals used as internal standards. ESI-MS (including HR-ESI-MS) were measured on API QSTAR Pulsar i mass spectrometers. Silica gel (200--300 mesh, Qingdao Marine Chemical Inc., China) and Sephadex LH-20 (Amersham Biosciences, Sweden) were used for column chromatography. Medium pressure liquid chromatography (MPLC) was performed on a Büchi Sepacore System equipping with pump manager C-615, pump modules C-605, and fraction collector C-660 (Büchi Labortechnik AG, Switzerland), and columns packed with Chromatorex C-18 (40--75 μm, Fuji Silysia Chemical Ltd., Japan). Fractions were monitored by TLC (Qingdao Marine Chemical Inc., China) in combination with reversed-phase HPLC (Agilent 1200, Extend-C18 column, 5 μm, 4.6 × 150 mm).

Plant Material {#Sec5}
--------------

The aerial parts of *Rauvolfia tetraphylla* were collected in Xiaomenglun of Yunnan Province, China, in June 2010 and identified by Mr. Yu Chen of Kunming Institute of Botany, Chinese Academy of Sciences. The voucher specimen (No. BBP0234020RT) was deposited at BioBioPha Co., Ltd.

Extraction and Isolation {#Sec6}
------------------------

The air-dried and powdered aerial parts of *R. tetraphylla* (7.5 kg) were extracted three times with EtOH-H~2~O (95:5, v/v; 3 × 20 L, each 5 days) at room temperature, and the solvent was removed under reduced pressure to give crude extract (ca. 400 g), which was then fractionated by silica gel column chromatography (CC) eluted with a gradient solvent system (containing 0.2 % ammonia) of petroleum ether-acetone and then MeOH to yield seven fractions A--G. Fraction D, eluted by acetone, was separated on silica gel CC (CHCl~3~--MeOH--ammonia, 100:1:0.5 → 0:100:0.5) to give three subfractions D1--D3. Fraction D1 was purified further by silica gel CC (CHCl~3~--MeOH--ammonia, 50:1:0.1) and then prep. TLC (CHCl~3~--MeOH--ammonia, 10:1:0.1) to afford **4** (9 mg) and **5** (6 mg). Fraction D2 was separated by silica gel CC (CHCl~3~--MeOH--ammonia, 40:1:0.1) and then prep. TLC (CHCl~3~--MeOH--ammonia, 9:1:0.1) to afford **3** (10 mg). Fraction G, eluted by MeOH, was separated further by silica gel CC (CHCl~3~--MeOH--ammonia, 10:1:0.1 → 0:10:0.1), repeated MPLC (40 → 45 % MeOH in H~2~O), and then Sephadex LH-20 (MeOH) to afford **1** (72 mg) and **2** (26 mg).

Rauvotetraphylline F (**1**) {#Sec7}
----------------------------

White amorphous powder; \[α\]~D~^15^ +10.1 (*c* 0.19, CHCl~3~); UV (MeOH) *λ*~max~: 225, 281, 290 (sh) nm; IR (KBr) *ν*~max~ 3404, 2961, 2921, 1700, 1470, 1453, 1384, 1338, 1320, 1302, 1076, 1031, 745 cm^−1^; ^1^H and ^13^C NMR data see Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}; ESI-MS (pos.): *m/z* 568 \[M + H\]^+^; HR-ESI-MS (pos.): *m/z* 568.3025 (calcd for C~31~H~42~N~3~O~7~, 568.3022).

17-*epi*-Rauvotetraphylline F (**2**) {#Sec8}
-------------------------------------

White amorphous powder; \[α\]~D~^16^ +14.9 (*c* 0.20, CHCl~3~); UV (MeOH) *λ*~max~: 225, 281, 290 (sh) nm; IR (KBr) *ν*~max~ 3396, 2962, 2923, 1699, 1626, 1471, 1451, 1384, 1337, 1300, 1075, 1030, 746 cm^−1^; ^1^H and ^13^C NMR data see Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}; ESI-MS (pos.): *m/z* 568 \[M + H\]^+^; HR-ESI-MS (pos.): *m/z* 568.3031 (calcd for C~31~H~42~N~3~O~7~, 568.3022).

Rauvotetraphylline G (**3**) {#Sec9}
----------------------------

White amorphous powder; \[α\]~D~^14^ −22.4 (*c* 0.19, CHCl~3~); UV (MeOH) *λ*~max~: 225, 280, 290 (sh) nm; IR (KBr) *ν*~max~ 3421, 3143, 3057, 2961, 2925, 2855, 1705, 1626, 1473, 1301, 1240, 1169, 741 cm^−1^; ^1^H and ^13^C NMR data see Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}; ESI-MS (pos.): *m/z* 390 \[M + H\]^+^; HR-ESI-MS (pos.): *m/z* 390.2538 (calcd for C~25~H~32~N~3~O, 390.2545).

Rauvotetraphylline H (**4**) {#Sec10}
----------------------------

White amorphous powder; \[α\]~D~^14^ +9.9 (*c* 0.20, CHCl~3~); UV (MeOH) *λ*~max~: 220, 262 nm; IR (KBr) *ν*~max~ 3433, 2965, 2934, 1741, 1707, 1592, 1453, 1380, 1364, 1295, 1033, 773, 753 cm^−1^; ^1^H and ^13^C NMR data see Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}; ESI-MS (pos.): *m/z* 448 \[M + H\]^+^; HR-ESI-MS (pos.): *m/z* 448.2613 (calcd for C~27~H~34~N~3~O~3~, 448.2600).

17-*epi*-Rauvotetraphylline H (**5**) {#Sec11}
-------------------------------------

White amorphous powder; \[α\]~D~^15^ +47.3 (*c* 0.20, CHCl~3~); UV (MeOH) *λ*~max~: 220, 263 nm; IR (KBr) *ν*~max~ 3433, 2965, 2936, 1742, 1707, 1592, 1453, 1376, 1268, 1230, 1177, 1032, 774, 753 cm^−1^; ^1^H and ^13^C NMR data see Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}; ESI-MS (pos.): *m/z* 448 \[M + H\]^+^; HR-ESI-MS (pos.): *m/z* 448.2602 (calcd for C~27~H~34~N~3~O~3~, 448.2600).

Cytotoxicity Bioassay {#Sec12}
---------------------

The cytotoxicity assay was performed according to an MTT \[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide\] method \[[@CR14]\], by use of the following five human cancer cell lines: HL-60, SMMC-7721, A-549, MCF-7, and SW-480. The IC~50~ values were calculated by Reed and Muench's method \[[@CR15]\].
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